Department of Radiological Sciences, David Geffen School of Medicine at University of California Los Angeles, 10945 Le Conte Avenue, Suite # 3371. Los Angeles, CA 90095-7206, United States.
Eur J Radiol. 2011 Oct;80(1):2-8. doi: 10.1016/j.ejrad.2011.01.092. Epub 2011 Apr 1.
Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.
在过去的十年中，三维对比增强磁共振血管造影（CE-MRA）已成为一种广泛接受的强大技术，可用于诊断评估几乎所有血管区域。其非侵入性和无电离辐射、覆盖大视野的潜力以及基于钆的造影剂的安全性，使得 CE-MRA 成为数字减影血管造影（DSA）或计算机断层血管造影（CTA）的一种有吸引力的替代方法。然而，最近有报道将高剂量基于钆的造影剂与肾源性系统性纤维化的发展联系起来[1-3]，这引起了人们对 CE-MRA 安全性的关注。因此，许多研究人员将注意力集中在降低钆剂量的策略上[4,5]。本文综述了现有的最先进的 3D CE-MRA 策略，以降低对比剂剂量，并总结了迄今为止的现有应用和临床经验。它还强调了不断发展的技术，作者认为这些技术可能会增强 CE-MRA 的未来影响。
